Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Effectiveness of mRNA-1273 against infection and COVID-19 hospitalization with SARS-CoV-2 Omicron subvariants: BA.1, BA.2, BA.2.12.1, BA.4, and BA.5

Hung Fu Tseng, Bradley K. Ackerson, Katia J. Bruxvoort, View ORCID ProfileLina S. Sy, Julia E. Tubert, Gina S. Lee, Jennifer H. Ku, View ORCID ProfileAna Florea, Yi Luo, Sijia Qiu, Soon Kyu Choi, Harpreet S. Takhar, Michael Aragones, Yamuna D. Paila, Scott Chavers, Carla A. Talarico, View ORCID ProfileLei Qian
doi: https://doi.org/10.1101/2022.09.30.22280573
Hung Fu Tseng
1Kaiser Permanente Southern California, 100 S Los Robles Ave., Pasadena, CA 91101, USA
2Kaiser Permanente Bernard J. Tyson School of Medicine, 98 S. Los Robles Ave., Pasadena, CA 91101, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Hung-Fu.X.Tseng@kp.org
Bradley K. Ackerson
1Kaiser Permanente Southern California, 100 S Los Robles Ave., Pasadena, CA 91101, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katia J. Bruxvoort
1Kaiser Permanente Southern California, 100 S Los Robles Ave., Pasadena, CA 91101, USA
3University of Alabama at Birmingham, 1665 University Blvd, Birmingham, AL 35233, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lina S. Sy
1Kaiser Permanente Southern California, 100 S Los Robles Ave., Pasadena, CA 91101, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Lina S. Sy
Julia E. Tubert
1Kaiser Permanente Southern California, 100 S Los Robles Ave., Pasadena, CA 91101, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gina S. Lee
1Kaiser Permanente Southern California, 100 S Los Robles Ave., Pasadena, CA 91101, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer H. Ku
1Kaiser Permanente Southern California, 100 S Los Robles Ave., Pasadena, CA 91101, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ana Florea
1Kaiser Permanente Southern California, 100 S Los Robles Ave., Pasadena, CA 91101, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ana Florea
Yi Luo
1Kaiser Permanente Southern California, 100 S Los Robles Ave., Pasadena, CA 91101, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sijia Qiu
1Kaiser Permanente Southern California, 100 S Los Robles Ave., Pasadena, CA 91101, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Soon Kyu Choi
1Kaiser Permanente Southern California, 100 S Los Robles Ave., Pasadena, CA 91101, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harpreet S. Takhar
1Kaiser Permanente Southern California, 100 S Los Robles Ave., Pasadena, CA 91101, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Aragones
1Kaiser Permanente Southern California, 100 S Los Robles Ave., Pasadena, CA 91101, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yamuna D. Paila
4Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott Chavers
4Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carla A. Talarico
4Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lei Qian
1Kaiser Permanente Southern California, 100 S Los Robles Ave., Pasadena, CA 91101, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Lei Qian
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Studies have reported reduced natural SARS-CoV-2 infection- and vaccine-induced neutralization against Omicron BA.4/BA.5 compared with earlier Omicron subvariants. We conducted a test-negative case–control study evaluating mRNA-1273 vaccine effectiveness (VE) against infection and hospitalization with Omicron subvariants. The study included 30,809 SARS-CoV-2 positive and 92,427 SARS-CoV-2 negative individuals aged ≥18 years tested during 1/1/2022-6/30/2022. While 3-dose VE against BA.1 infection was high and waned slowly, VE against BA.2, BA.2.12.1, BA.4, and BA.5 infection was initially moderate to high (61.0%-90.6% 14-30 days post third dose) and waned rapidly. The 4-dose VE against infection with BA.2, BA.2.12.1, and BA.4 ranged between 64.3%-75.7%, and was low (30.8%) against BA.5 14-30 days post fourth dose, disappearing beyond 90 days for all subvariants. The 3-dose VE against hospitalization for BA.1, BA.2, and BA.4/BA.5 was 97.5%, 82.0%, and 72.4%, respectively; 4-dose VE against hospitalization for BA.4/BA.5 was 88.5%. Evaluation of the updated bivalent booster is warranted.

Competing Interest Statement

HFT, BKA, LSS, JET, GSL, JHK, AF, YL, SQ, SKC, HST, MA, and LQ are employees of Kaiser Permanente Southern California, which has been contracted by Moderna to conduct this study. KJB is an adjunct investigator at Kaiser Permanente Southern California. YDP and SC are employees of and shareholders in Moderna, Inc. HFT received funding from GlaxoSmithKline unrelated to this manuscript; CAT was an employee of and a shareholder in Moderna Inc. at the time of these analyses; CAT is currently an employee of AstraZeneca; HFT also served on advisory boards for Janssen and Pfizer. BKA received funding from GlaxoSmithKline, Dynavax, Genentech, and Pfizer unrelated to this manuscript. KJB received funding from GlaxoSmithKline, Dynavax, Pfizer, and Gilead unrelated to this manuscript. LSS received funding from GlaxoSmithKline and Dynavax unrelated to this manuscript. JET received funding from Pfizer unrelated to this manuscript. GSL received funding from GlaxoSmithKline unrelated to this manuscript. JHK received funding from GlaxoSmithKline unrelated to this manuscript. AF received funding from Pfizer, GlaxoSmithKline, and Gilead unrelated to this manuscript. YL received funding from GlaxoSmithKline and Pfizer unrelated to this manuscript. SQ received funding from Dynavax unrelated to this manuscript. SKC received funding from Pfizer and the Pancreatic Cancer Action Network unrelated to this manuscript. HST received funding from GlaxoSmithKline, Pfizer, ALK, and Wellcome unrelated to this manuscript. MA received funding from Pfizer unrelated to this manuscript. LQ received funding from GlaxoSmithKline and Dynavax unrelated to this manuscript.

Funding Statement

This study was funded by Moderna, Inc. Employees of Moderna participated in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication. All authors from KPSC had full access to all the data and can take responsibility for integrity of data and accuracy of data analysis. Assistance in writing and formatting of the manuscript were provided by Srividya Ramachandran and Jared Mackenzie of MEDiSTRAVA in accordance with Good Publication Practice (GPP3) guidelines, funded by Moderna, and under the direction of the authors.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was reviewed and approved by the KPSC Institutional Review Board (IRB #12758). All study staff with access to protected health information were trained in procedures to protect the confidentiality of subject data. A waiver of informed consent was obtained as this is an observational study of authorized and recommended Moderna COVID-19 vaccine administered in the course of routine clinical care. To facilitate the conduct of this study, a waiver was obtained for written HIPAA authorization for research involving use of the EHR.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵* Moderna Inc. employee at the time of the study.

  • Carla A. Talarico was inadvertently missed from the author byline. The author line and competing interests sections have been updated.

Data Availability

Individual-level data reported in this study are not publicly shared. Upon reasonable request and subject to review, KPSC may provide the de-identified aggregate-level data that support the findings of this study. De-identified data may be shared upon approval of an analysis proposal and a signed data access agreement.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted December 02, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Effectiveness of mRNA-1273 against infection and COVID-19 hospitalization with SARS-CoV-2 Omicron subvariants: BA.1, BA.2, BA.2.12.1, BA.4, and BA.5
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Effectiveness of mRNA-1273 against infection and COVID-19 hospitalization with SARS-CoV-2 Omicron subvariants: BA.1, BA.2, BA.2.12.1, BA.4, and BA.5
Hung Fu Tseng, Bradley K. Ackerson, Katia J. Bruxvoort, Lina S. Sy, Julia E. Tubert, Gina S. Lee, Jennifer H. Ku, Ana Florea, Yi Luo, Sijia Qiu, Soon Kyu Choi, Harpreet S. Takhar, Michael Aragones, Yamuna D. Paila, Scott Chavers, Carla A. Talarico, Lei Qian
medRxiv 2022.09.30.22280573; doi: https://doi.org/10.1101/2022.09.30.22280573
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Effectiveness of mRNA-1273 against infection and COVID-19 hospitalization with SARS-CoV-2 Omicron subvariants: BA.1, BA.2, BA.2.12.1, BA.4, and BA.5
Hung Fu Tseng, Bradley K. Ackerson, Katia J. Bruxvoort, Lina S. Sy, Julia E. Tubert, Gina S. Lee, Jennifer H. Ku, Ana Florea, Yi Luo, Sijia Qiu, Soon Kyu Choi, Harpreet S. Takhar, Michael Aragones, Yamuna D. Paila, Scott Chavers, Carla A. Talarico, Lei Qian
medRxiv 2022.09.30.22280573; doi: https://doi.org/10.1101/2022.09.30.22280573

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (228)
  • Allergy and Immunology (504)
  • Anesthesia (110)
  • Cardiovascular Medicine (1240)
  • Dentistry and Oral Medicine (206)
  • Dermatology (147)
  • Emergency Medicine (282)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (531)
  • Epidemiology (10023)
  • Forensic Medicine (5)
  • Gastroenterology (499)
  • Genetic and Genomic Medicine (2453)
  • Geriatric Medicine (238)
  • Health Economics (479)
  • Health Informatics (1643)
  • Health Policy (753)
  • Health Systems and Quality Improvement (636)
  • Hematology (248)
  • HIV/AIDS (533)
  • Infectious Diseases (except HIV/AIDS) (11864)
  • Intensive Care and Critical Care Medicine (626)
  • Medical Education (252)
  • Medical Ethics (75)
  • Nephrology (268)
  • Neurology (2281)
  • Nursing (139)
  • Nutrition (352)
  • Obstetrics and Gynecology (454)
  • Occupational and Environmental Health (537)
  • Oncology (1245)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (158)
  • Palliative Medicine (50)
  • Pathology (324)
  • Pediatrics (730)
  • Pharmacology and Therapeutics (313)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2280)
  • Public and Global Health (4834)
  • Radiology and Imaging (837)
  • Rehabilitation Medicine and Physical Therapy (492)
  • Respiratory Medicine (651)
  • Rheumatology (285)
  • Sexual and Reproductive Health (238)
  • Sports Medicine (227)
  • Surgery (267)
  • Toxicology (44)
  • Transplantation (125)
  • Urology (99)